ストックスクリーナーアプリを入手
1.54
4.76%
0.07
アフターアワーズ：
1.54
前日終値:
$1.47
開ける：
$1.46
24時間の取引高:
206.57K
Relative Volume:
0.44
時価総額：
$65.05M
収益：
$88.55M
当期純損益:
$-53.21M
株価収益率:
-1.1902
EPS:
-1.2939
ネットキャッシュフロー:
$-29.48M
1週間 パフォーマンス:
+10.79%
1か月 パフォーマンス:
+7.69%
6か月 パフォーマンス:
-24.51%
1年 パフォーマンス:
-41.89%
1日の値動き範囲:
$1.43
$1.55
1週間の範囲:
$1.3874
$1.55
52週間の値動き範囲:
$1.13
$3.88
Pulmonx Corp Stock (LUNG) Company Profile
Compare LUNG vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LUNG
Pulmonx Corp
|
1.54 | 62.09M | 88.55M | -53.21M | -29.48M | -1.2939 |
ABT
Abbott Laboratories
|
93.93 | 164.43B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 125.40B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 105.46B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.87B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 52.59B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pulmonx Corp Stock (LUNG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-31 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-03-10 | 開始されました | D. Boral Capital | Buy |
| 2024-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-06-04 | 開始されました | Lake Street | Buy |
| 2024-02-23 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-09-05 | 開始されました | Craig Hallum | Buy |
| 2023-02-27 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-12-12 | アップグレード | Citigroup | Neutral → Buy |
| 2022-07-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-03-02 | 再開されました | BofA Securities | Neutral |
| 2021-12-08 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-04-01 | 開始されました | Citigroup | Buy |
| 2021-03-25 | 開始されました | Piper Sandler | Neutral |
| 2021-03-10 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-10-26 | 開始されました | BofA Securities | Buy |
| 2020-10-26 | 開始されました | Canaccord Genuity | Buy |
| 2020-10-26 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-10-26 | 開始されました | Stifel | Buy |
| 2020-10-26 | 開始されました | Wells Fargo | Equal Weight |
すべてを表示
Pulmonx Corp (LUNG) 最新ニュース
Pulmonx (NASDAQ:LUNG) Sparks Fresh Penny Stock Buzz - Kalkine Media
Pulmonx Corp highlights lung device strategy as a specialized medtech player - ad-hoc-news.de
Enterprise value to EBITDA forward of Pulmonx Corp. – LSX:A2P1AF - TradingView
Price to earnings forward of Pulmonx Corp. – LSX:A2P1AF - TradingView
Price to sales forward of Pulmonx Corp. – DUS:4NI - TradingView
Pulmonx Corp highlights its respiratory device portfolio as investors assess long-term growth prospe - ad-hoc-news.de
LUNG News | PULMONX CORP (NASDAQ:LUNG) - ChartMill
Pulmonx Corp (LUNG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pulmonx Corp. Actuals & Estimates (NASDAQ:LUNG) - TradingView
Pulmonx Corp (LUNG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pulmonx Corp (LUNG) Institutional Confidence - TradingKey
Pulmonx Corp (LUNG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pulmonx Corp (LUNG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pulmonx Corp (LUNG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pulmonx Corp (LUNG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pulmonx Corp (LUNG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pulmonx Corp (LUNG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LUNG SEC FilingsPulmonx Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Pulmonx (LUNG) awards 40,000 restricted stock units to director - Stock Titan
Director Ferrari (LUNG) awarded 40,000 Pulmonx restricted stock units - Stock Titan
Pulmonx Corp (LUNG) director granted 40,000 restricted stock units - Stock Titan
[Form 4] Pulmonx Corp Insider Trading Activity - Stock Titan
Pulmonx (LUNG) director receives 40,000-share RSU stock grant - Stock Titan
Don't Ignore The Insider Selling In Pulmonx - Sahm
Pulmonx (NASDAQ: LUNG) investors back board, auditor and executive pay - Stock Titan
Pulmonx general counsel David Lehman sells $22,474 in stock - Investing.com UK
Pulmonx general counsel David Lehman sells $22,474 in stock By Investing.com - Investing.com India
Pulmonx (LUNG) officer sells 14,497 shares to cover RSU tax withholding - Stock Titan
Pulmonx (LUNG) General Counsel sells 14,594 shares to cover RSU tax obligations - Stock Titan
Pulmonx (LUNG) CCO sells shares to cover RSU tax obligations - Stock Titan
Pulmonx (LUNG) CEO logs 56K-share sale tied to RSU tax withholding - Stock Titan
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
17 Pulmonx hires receive 84,300 RSUs in Nasdaq inducement plan - Stock Titan
Pulmonx (LUNG) Q1 2026 Earnings Transcript - AOL.com
LUNGPulmonx Corp Stock Price and Quote - Finviz
QTEX Stock Price and Chart — NASDAQ:QTEX - TradingView
Pulmonx (LUNG) Holds Steady Near $1.54 as Key Support and Resistance Levels Define Trading RangeProtective Put - The Legal Advocate
Pulmonx Corp stock (US74586W1018): Q1 2026 results highlight growth path in minimally invasive lung - AD HOC NEWS
Pulmonx Corp stock (US74586W1018): credit line and margin focus keep lung care specialist in the spo - AD HOC NEWS
LUNG Technical Analysis | Trend, Signals & Chart Patterns | PULMONX CORP (NASDAQ:LUNG) - ChartMill
TradingKey - TradingKey
Why Pulmonx Corporation (LUNG) valuation makes sense when you dig deeper (Marginal Loss) 2026-05-11Buffered ETF - Newser
Pulmonx Corporation (LUNG) beats Q1 estimates with EPS improvement despite revenue growth; shares decline as investors focus on losses.AI Trading Community - Newser
Pulmonx Corporation Q1 2026 Financial Report Highlights, Forward-Looking Statements, and Key Risk Factors - Minichart
Pulmonx (NASDAQ: LUNG) secures $40M Perceptive loan and ends Q1 with $61.6M cash - Stock Titan
Pulmonx Corp 1Q 2026: Revenue $20.59M, EPS ($0.33) — 10-Q Summary - TradingView
Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Pulmonx (NASDAQ:LUNG) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Pulmonx Corporation (NASDAQ:LUNG) Q1 2026 Earnings Call Transcript - Insider Monkey
LUNG Maintained by D. Boral Capital -- Price Target Stays at $14 - GuruFocus
Pulmonx Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Pulmonx Corp (LUNG) 財務データ
収益
当期純利益
現金流量
EPS
Pulmonx Corp (LUNG) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lehman David Aaron | GENERAL COUNSEL |
Jun 01 '26 |
Sale |
1.54 |
14,594 |
22,475 |
376,161 |
| Rose Geoffrey Beran | CHIEF COMMERCIAL OFFICER |
Jun 01 '26 |
Sale |
1.54 |
8,023 |
12,355 |
457,711 |
| French Glendon E. III | President and CEO |
Jun 01 '26 |
Sale |
1.54 |
42,638 |
65,663 |
1,191,673 |
| French Glendon E. III | President and CEO |
Jun 02 '26 |
Sale |
1.57 |
13,511 |
21,212 |
1,178,162 |
| Radhakrishnan Srikanth | Chief Science &Techn. Officer |
Mar 02 '26 |
Sale |
1.43 |
10,483 |
14,991 |
170,736 |
| French Glendon E. III | President and CEO |
Mar 02 '26 |
Sale |
1.43 |
67,813 |
96,973 |
1,409,511 |
| Rose Geoffrey Beran | CHIEF COMMERCIAL OFFICER |
Mar 02 '26 |
Sale |
1.43 |
7,732 |
11,057 |
365,734 |
| Lehman David Aaron | GENERAL COUNSEL |
Mar 02 '26 |
Sale |
1.43 |
12,237 |
17,499 |
240,755 |
2.36%
大文字化:
|
ボリューム (24 時間):